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Impact statement 
The epidemiology of vulvar cancer (VSCC) is changing. Our data reveal that 
the age at which women are diagnosed with VSCC is falling. High-risk (HR) 
human papillomavirus (HPV) infection is very common in vulvar intraepithelial 
neoplasia (VIN) and present in just over 50% of VSCC. HR-HPV positivity was 
associated with lower progression rates from VIN to VSCC and improved 
progression-free survival of VSCC. 
 
Short Title: HPV positivity correlates with improved outcome in invasive 
vulvar cancer. 
 
Submitted to: Infectious Causes of Cancers 
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Abbreviations: 
HPV, human papillomavirus 
HR-HPV, high risk- human papillomavirus  
VSCC, Vulvar squamous cell cancer 
VIN, Vulvar intraepithelial neoplasia,  
CIN, cervical intraepithelial neoplasia 
OPSCC, oropharyngeal squamous cell cancer  
LSIL low grade squamous intraepithelial lesion 
HSIL high grade squamous intraepithelial lesion 
(FFPE), formalin fixed, paraffin-embedded 
NOS, not otherwise specified 
NA, nucleic acid 
SIMD, Scottish Index of Multiple Deprivation  
OS, overall survival  
PFS, progression free survival  
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Abstract  
 
It is universally accepted that high-risk human papillomavirus (HR-HPV) is the 
cause of cervical dysplasia and cancer. More recently it has been shown that 
HPV is also a marker of clinical outcome in oropharyngeal cancer. However, 
contemporary information is lacking on both the prevalence of HPV infection in 
vulvar cancer (VSCC), its precursor lesion, vulvar intraepithelial neoplasia (VIN) 
and the influence of HPV-status on the prognosis of this malignancy. We have 
conducted a detailed population-based study to examine rates of progression 
of VIN to VSCC, type-specific HPV prevalence in vulvar disease and the 
influence of HPV status on clinical outcome in VSCC. We observed that the 
age at which women are diagnosed with VSCC is falling and there is a 
significant time gap between first diagnosis of VIN and progression to invasive 
disease. HR-HPV infection was detected in 87% (97/112) cases of VIN and 
52% cases (32/62) of VSCC. The presence of HR-HPV in squamous 
intraepithelial lesion was associated with lower rates of progression to invasive 
cancer (hazard ratio, 0.22, p=0.001).   In the adjusted analysis, HR-HPV was 
associated with improved progression-free survival of VSCC compared to those 
with HPV negative tumours (hazard ratio, 0.32, p=0.02). 
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Introduction 
 
Squamous cell cancer of the vulva accounts for about 3-4% of genital cancers 
among women with an estimated 30,000 new cases diagnosed per year 
worldwide. 1 There is evidence that vulvar squamous cell cancer (VSCC) and 
its precursor lesion, vulvar intraepithelial neoplasia (VIN) is increasing. 
Recently, we reported that the incidence of vulvar cancer in Scotland has 
increased by about 64% in the past three decades, particular among young 
women. 2, 3  The reasons behind the changing epidemiology of vulval disease 
are unclear but it may be driven by a secular increase in HPV infection and/or 
changed behaviors that have facilitated the transmission. 
 
The estimates of HPV prevalence in VIN reported in an international meta-
analysis were 84%.4 VIN is challenging to manage - surgical or topical 
treatment can be associated with significant morbidities. Natural history studies 
indicate that around 10% of VIN will progress to cancer although 
comprehensive, global data are relatively sparse when compared to other HPV-
associated neoplasms.5 For cervical intraepithelial neoplasia (CIN) the 
estimated spontaneous regression rate is between 30 and 50%, with about 10 
to 40% progressing to invasive cancer if untreated.6 Factors that predict 
progression of VIN to invasive disease are poorly characterised. 
 
HPV status is considered a marker of favorable clinical outcome in 
oropharyngeal squamous cell cancer (OPSCC) compared to HPV-negative 
tumours.7 As nearly all cervical cancers are positive for HPV, few studies have 
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looked at HPV status and clinical outcome, although there is some evidence to 
suggest that cancers where HPV is not detectable have a worse prognosis.8 
Although the global data on HPV type-specific epidemiology in VSCC are less 
comprehensive compared to cervical cancer and OPSCC, current estimates 
indicate that approximately 20% of VSCC are associated with HPV. 9 However, 
data on the influence of HPV-status on the prognosis of patients with vulvar 
cancer is either lacking or conflicting. 
 
Two recent publications have reported that among women with VSCC the 
presence of HPV-DNA in tumour tissue is an independent prognostic factor 
associated with a favourable outcome.10, 11 Studies have also reported tumours 
expressing p16, a biomarker associated with HPV positivity12 are less likely to 
recur.10, 13 In contrast, Alonso et al investigated presence of HPV DNA with 
response to radiotherapy; in multivariable analysis only the presence of lymph 
nodes metastasis was associated with outcome.14  A similar finding was 
reported by another study15, that in the presence of lymph node metastasis, 
HPV status if the vulvar lesion was not predictive of outcome.  
 
Given the aforementioned knowledge gaps, the aim of the present study was 
to characterize VIN and VSCC in a population-based series of patients with 
respect to (1) progression of VIN to VSCC (2) type-specific HPV prevalence 
and (3) influence of HPV status on clinical outcome/prognosis in VSCC.  
Scotland Is an ideal location for a study of a relative rare cancer such as VSCC 
due to the almost complete population uptake of health care through the 
National Health Service 16 and consistent national coverage of collection of 
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health service data.17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
 7 
 
Case selection and identification  
All cases of VIN and VSCC diagnosed between 01/01/2001 and 31/12/2014 
were identified using the National Health Service, Greater Glasgow and Clyde 
pathology database, a prospectively gathered record of all routine pathology 
reports that links to a bio-repository archive of all processed tissue. The Health 
Board covers the following locations: West Dunbartonshire; East 
Dunbartonshire; East Renfrewshire; Glasgow City; Inverclyde and 
Renfrewshire and covers a population of approximately 1.1 million people with 
about 50% of these being women.18 Health services in Scotland are financed 
almost entirely out of general taxation and available to all inhabitants, with only 
a very small independent health care sector.16 VIN lesions were graded as part 
of routine National Health Service management as not otherwise specified 
(NOS) µORZ JUDGH¶ /6,/9,1 RU µKLJK JUDGH¶ +6,/9,1 RU  G\VSODVLD. 
Women often had multiple biopsies taken of a disease episode over a short 
time period and so the study population was divided into the following four 
groups to reduce misclassification of concurrent diagnosis as sequential 
disease: 1. All VIN lesions identified within 365 days of each other were treated 
as a single episode of VIN; 2. VIN recurrence was defined as two positive 
biopsies separated by 365 days or more; 3. VSCC defined as an incident case 
of cancer diagnosed within the study period; and 4. VIN progressing to VSCC, 
where 365 days or more separated the diagnoses of VIN and VSCC.  
 
 
Identification, retrieval and review of cases 
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To allow pathology review and HPV genotyping, tissue was retrieved from the 
National Health Service, Greater Glasgow and Clyde pathology biobank for 
cases of VIN and non-metastatic VSCC diagnosed between 01/01/2008 and 
31/12/2009. Detailed pathology review including classifying cases using the 
2015 International Society for the Study of vulvovaginal disease (ISSVD) 
terminology of vulvar squamous intraepithelial lesions into low-grade squamous 
intraepithelial lesion (LSIL) and high-grade SIL (HSIL) and differentiated vulvar 
intraepithelial neoplasia (dVIN). To enable analysis of VIN recurrence or VSCC 
progression and associated pathological and viral factors in this cohort, any 
samples taken between 01/01/2001 and 31/12/2014 from these women were 
also reviewed and sent for HPV genotyping.  All retrieved tissue underwent 
pathology review by two consultant pathologists.  
 
VIN and VSCC case management 
For the duration of this study patients were managed within the National Health 
Service, Greater Glasgow and Clyde, tertiary gynaecology oncology referral 
centre, which offered dedicated vulval clinics for patients with VIN and VSCC.  
For VIN and VSCC cases the treatment philosophy was based on surgery 
during this time frame, aiming for a 1cm margin based on clinical findings at the 
time of surgery.  Where positive margins were identified after the primary 
excision then re-excision would be considered to achieve clear margins. 
However, this decision would be taken on an individual case basis. All patients 
were followed up in the tertiary gynaecology oncology referral centre at least 
twice per year with a physical examination and radiological procedure in cases 
of VSCC.  
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HPV genotyping 
Formalin fixed, paraffin-embedded blocks were selected and a 10 ȝm section 
obtained for subsequent nucleic acid (NA) extraction and HPV genotyping. NA 
extraction was performed.19 Subsequently, HPV genotyping was performed 
using the Optiplex HPV Genotyping assay (Diamex, Heidelberg, Germany). 
This assay detects 24 HPV types including all established oncogenic or high 
risk (HR)-types and, as a check for specimen adequacy, incorporates a cellular 
housekeeping control (beta globin). Immunohistochemical staining for p16 was 
carried out using BD Pharmingen p16 (Cat No51-1325GR). Cases were coded 
negative if staining was negative or focal and positive if staining diffuse.                                         
 
Annotation of cases with clinical information  
The demographic and clinical data/variables collected were age, FIGO cancer 
stage,20 treatment modality, immunosuppression, smoking status, date and 
cause of death and Scottish Index of Multiple Deprivation (SIMD) quintiles 
which identifies small area concentrations of multiple deprivation.21  Date of 
diagnosis was taken as date of pathology sample collection.  
 
Analysis 
Analysis of factors associated with HR-HPV infection was carried out in Stata12 
(StataCorp LP, College Station, TX). Kappa scores for agreement between HR-
HPV genotype status and p16 positivity were calculated. Associations between 
HPV-status and clinical variables were estimated using the Pearson chi-
squared test. Both unadjusted and adjusted odds ratios (ORs) for HPV positivity 
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and 95% confidence intervals (CIs) were calculated using logistic regression 
modeling. For women with VIN, rates of recurrent or progressive disease by 
HPV status and co-factors were estimated accounting for differing person years 
of contribution for each individual.  The univariate association between 
recurrent and progressive disease and each of the clinical variables were 
assessed using Cox proportional-hazards models. 
 
In those with VSCC, rates of overall survival and progression-free survival were 
estimated by means of the Kaplan±Meier method and Cox proportional-
hazards models were used to estimate unadjusted hazard ratios for all of the 
clinical variables. A fully adjusted model was created using all variables and 
then backwards selection used to remove insignificant variables at each stage 
resulting in final adjusted hazard ratios to estimate the difference in survival by 
HR HPV- status. All Cox proportional-hazards models were run using R version 
3.2.3. 
 
All P-values were 2-sided and we considered P <0.05 to be statistically 
significant. 
 
 
 
 
Governance 
Permission was gained from National Health Service Greater Glasgow and 
Clyde (Biorepository Reference Number 96). 
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Results 
 
Prevalence of VIN and VSCC between 2001-2014 and association with age 
at diagnosis 
There were 6666 pathology specimens of benign and malignant vulvar tissue 
and of these, there were 949 individual women with either VIN or VSCC 
identified. Incident cases during the selected time period of VSCC accounted 
for 43% (404/949) of samples and VIN, 57% (545/949).  Table 1 describes the 
cases pathological categories and age. The median age of diagnosis of VSCC 
decreased from 76 years (IQR 64-89) in 2001 to 64 years (IQR 50-78) in 2014. 
The median age at VSCC diagnosis was significantly older compared to women 
presenting with a diagnosis of pre-invasive disease (65 Vs 47 years [p<0.001]).  
 
Underlying pathology of VIN and VSCC and rates of progression between 
2001-2014 
In this cohort for samples collected between 2001 and 2014, the prevalence of 
recurrent VIN and VIN progressing to VSCC was 18% (96/545) and 6% 
(32/545), respectively.  The median time that women had recorded episodes of 
recurrent VIN (with no documented pathology of VSCC) was 3.1 years (range 
1.7-14.3 years). The median time from first recorded VIN to VSCC was 2.8 
years (range 1.1 to 9.1 years). When using the pathology scores recorded for 
National Health Service management, no association was found between 
grade of lesion (low grade versus high grade) and risk of VIN recurrence (p=0.9) 
or progression to cancer (p=0.7).  
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VIN and VSCC pathology for detailed subset between 2008 and 2009 
A subset of the above cases diagnosed between 01/01/2008 and 31/12/2009 
were selected for HPV genotyping (Table 1). This time period was chosen on 
the basis complete case ascertainment of pathology specimens and to allow 
length of time of follow-up for survival analysis. Two cases were associated with 
immunosuppressive drug administration to prevent transplant rejection.  
 
The five-year overall survival for women less than 60 years, 60 years to 79 
years, and 80 years and older was 90%, 50% and 15% respectively.  Stage of 
cancer was also related to 5-year overall survival with FIGO Stage 1, 2 and 
3/4a having survival rates of 79%, 40% and 38% respectively.     
 
HPV type specific distribution in VIN  
For cases of VIN, valid results were obtained for 112/118 samples; two results 
were considered invalid when tests were negative for both HPV and beta globin, 
and four results were not available due to sampling/operational reasons.   HPV 
infection was identified in 87% cases (97/112) and HR-HPV types in 85% 
(95/112). Of cases where HPV was detected, single infections with 16, 18, 33, 
42, 45 and 51 were identified in 79, 2, 6, 2, 1 and 1 cases respectively.  The 
occurrence of multiple infections of 16/18, 16/33, 16/33/53, 16/42, 18/6 and 
16/6/11 all occurred in a single case each.  The level of agreement between 
HR-HPV genotype and p16 staining was strong (79%, P=0.001). 
 
In the adjusted multivariable analysis (Table 2) the odds of high-risk HPV-
positivity was higher in women with HSIL (p=0.04) compared to women with 
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LSIL or dVIN. Women with VIN staining positive for the biomarker p16 were 
also more likely to have pre-invasive disease associated with HR-HPV (p=0.04).  
 
 
Type specific persistence of HPV in women with recurrent VIN  
A total of 34/36 cases of VIN diagnosed between 01/01/2008 and 31/12/2009 
met study criteria for recurrent VIN and had valid HPV results. The HR-HPV 
was detected in 88% (30/34) of the first recorded samples and type specific 
infections were HPV 16 alone in 25/34 cases and 16/18, 16/33/53, 16/6/11, 33 
and 51 in one case each. Additional samples from these 34 cases, also 
separated by at least one year, were sought from the larger (01/01/2001 and 
31/12/2014) database. There were 65 such samples identified, with each 
woman having between 3 and 8 samples. The prevalence of HR-HPV positivity 
in the first biopsy sample for each case of recurrent VIN did not differ 
significantly from women with a single episode of VIN (88% [30/34] Vs 89% 
[58/65], p=0.7). Of the 34 recurrent VIN cases, the detection of HR-HPV was 
retained and did not change HPV sub-type in 28 cases, never detected in 3 
cases, lost from 2 cases and gained HPV in one. All gained and lost HPV types 
were 16. 
 
 
 
Type specific persistence of HPV in women with progressive VIN  
There were 13/14 women identified between 01/01/2008 and 31/12/2009 that 
met study criteria for VIN progressing to VSCC and had valid HPV results at 
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baseline. As above, additional samples for these women were also extracted 
from the larger (01/01/2001 and 31/12/2014) database.  Cases progressing 
from VIN to VSCC had between 1 and 9 biopsies (median=4) prior to a 
diagnosis of invasive cancer. The presence of HR-HPV in the baseline sample 
was less common in VIN from women whose disease progressed to VSCC 
compared to VIN that did not transform to cancer (89% [88/99] Vs 54% [7/13], 
p<0.001).  Among VIN cases that progressed to VSCC all HPV-positive cases 
(n=7) at baseline were associated with type 16 HPV alone.  Two HPV 16 
positive cases progressed to a HPV negative tumour. Nine of the fourteen 
cases had high-grade dysplasia reported at other perineal anatomical sites. 
 
Rates if recurrence and progression of VIN 
We next investigated the rate of recurrence VIN or VIN progressing to cancer 
by HR-HPV status and other clinical variables (Table 3).  VIN associated with 
HR-HPV had a lower rate of progression to cancer (HR 0.02, p=0.001). In 
addition, HSIL lesions compared to dVIN disease were less likely to progress 
to invasive disease (HR 0.17, p=0.003). There was also evidence that women 
older than 70 years of age had a higher rate of disease progressing to cancer 
(age 70-79 year HR 4.46, p=0.01 and women 80 years and over HR 20.92, 
p=0.001).  Women with dVIN tended to be older than woman with HSIL or LSIL 
(Table 1) and were less likely to be associated with HR-HPV (Table 2).  
HPV type specific distribution in VSCC 
Of the 66 cases of VSCC, valid HPV results were obtained from 62/66; three 
were classed invalid by testing both HPV negative and negative for beta globin 
and 1 was not available for operational reasons.  HPV infection was present in 
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52% cases (32/62) and all types identified were high-risk. HPV 16 was identified 
in 30 cases and type 31 and 33 in one case each. Only one case had dual HPV 
types; 16 and 42. There was almost perfect agreement between HR-HPV 
genotype and P16 positivity (82%, P<0.001). In the adjusted multivariable 
analysis (Table 4) the presence of VIN surrounding a tumour remained an 
independent predictor of HR-HPV positivity (p=0.003), as did positive staining 
for p16  (p=0.006). 
 
Influence of HPV status on survival in patients with VSCC 
The mean follow-up time from incident diagnosis was 5.8 years (range 55 days 
to 14 years). The 5-year rates of OS were 78% in the HR-HPV-positive group 
and 49% in the HPV-negative group. The 5-year rates of progression free 
survival (PFS) were 87% in the HR-HPV positive group and 47% in the negative 
group.  
 
In the unadjusted analysis, women with HR-HPV positive VSCC had better 
over-all survival (p=0.005, and progression-free survival (p=0.001)  (Tables 5 
and 6). After adjustment for age and cancer stage, patients with HPV-positive 
tumours had a 51% reduction in risk of death but the association was not 
statistically significant ((hazard ratio, 0.43, p=0.09) (Table 6). However, there 
was a statistically significant 70% reduction in risk of disease progression 
(hazard ratio, 0.32, p=0.02) compared to those with HPV negative tumours 
(Table 5).  
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Discussion 
 
We have conducted a detailed population-based study to examine rates of 
progression of VIN to VSCC and influence of clinical factors. Moreover, we have 
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determined type-specific HPV prevalence in vulvar disease and the influence 
of HPV status on clinical outcome in VSCC. Our data reveal key novel aspects 
of VIN and VSCC. In particular, the age at which women are diagnosed with 
VSCC is falling and there is a significant time gap between first diagnosis of 
VIN and progression to invasive disease. HR-HPV infection was very common 
in VIN and present in just over 50% of VSCC. Most importantly, detection of 
HR-HPV was associated with a reduction in risk of progression from VIN to 
cancer and associated with improved progression-free survival of VSCC. 
 
We have reported that the incidence of vulvar cancer in Scotland has increased 
by about 64% in the past three decades, particularly among young women.2, 3  
The above data indicate that the epidemiology of vulvar disease may be 
changing ± with the diagnosis of VSCC occurring at an earlier age according to 
this series. These findings are consistent with previous work in Scotland which 
showed that the European age-standardised ratio for VSCC between 1972±
1976 and 2007±2011, increased from 3.3 per 100,000 to 4.2 per 100,000 and 
that this increase was most prominent among younger women.3 These data 
also reconcile with the US study, which assessed VSCC data from nine US 
Cancer registries for the period 1973-2004 and showed that VIN and VSCC 
increased 3.5% and 1.0% respectively, each year with the increase observed 
in all categories but the largest increase occurred in women aged 54 or less.22  
 
Reasons for this phenomenon are unclear at present. It is feasible that changed 
clinical practices for the ascertainment and management of vulval disease may 
be influential in the case of VIN, but we do not believe this would be the case 
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for VSCC as cancer related symptoms and access to care have not appreciably 
changed between 2000 and 2014 in Scotland. Changed sexual behaviour(s), 
including age at first intercourse, which in turn facilitates transmission of HR-
HPV could result in increased incidence of disease. Evidence of a secular 
increase in HR-HPV prevalence has been reported elsewhere23 and the 
significant increase in HPV-associated oropharyngeal cancer over the last two 
decades may be due to an epidemic of highly transmissible HR-HPV.24  In 
addition, increased incidence of HR-HPV-positive oropharyngeal cancer has 
been partly attributed to changed sexual practices.25  Sexual behaviours 
associated with risk for vulval infection are considered similar to those for 
cervical infection and include age, single versus in partnership, age at first 
intercourse and number of sexual partners. 26 However, given that we did not 
specifically quantify or account for sexual behaviours in this study we are not 
able to address this directly and in fact there are few analyses on sexual 
behaviours and practices in women with VIN and VSCC ± particularly when 
compared to those undertaken in those with cervical or increasingly, head and 
neck cancer. In terms of risk of HPV acquisition and tobacco use,  smoking 
prevalence in Scotland remains higher than both England and Wales, there has 
been a downward trend from the mid-¶VWRWKHSUHVHQWWLPH27 
 
Clearly, it is of interest to promptly identify which women exhibit a greater 
chance of recurrence, which has a prevalence of about one-fifth of cases in this 
study.  The pathological grading of VIN as defined by National Health Service 
local practice, showed no association with recurrence and this may support the 
concept there is not a continuum with VIN lesions leading to cancer as 
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demonstrated for CIN and cervical cancer.28  Using the ISSVD terminology, 
cases of dVIN were more likely to recur or progress compared to LSIL and HSIL, 
but numbers were small.  While no other clinical factor studied identified risk of 
progression or recurrence of VIN, identifying the small number of women with 
dVIN, who tend to be older and HR-HPV negative for close active monitoring 
may be important.  
 
Another crucially important group to identify are those who have VIN that will 
progress to VSCC. In our series, the number of VIN cases that progressed to 
VSCC was between 6% and 10%. This figure is similar to that described in a 
recent analysis of 1094 Dutch women with VIN where the cumulative 20 year 
incidence was 8.9%.29 VIN associated with HR-HPV and categorised as HSIL 
had a lower rate of progression to cancer.  Younger women also appeared less 
likely to progress compared to women in older age groups. The results 
presented here suggest that VIN regression rates in HR-HPV associated high-
grade disease may be high.  This is important to characterised to prevent young 
women having extensive morbid surgical management of pre-invasive disease, 
which may regress. Low-grade cervical disease is characterised by transient 
infection while high-grade disease is due to subsequent persistent HPV 
infection.  Our data suggest that in many cases, VIN progression to VSCC may 
not follow this pathway. Our data was limited due to small numbers and use of 
a retrospective cases series. A study using a much larger patient group will be 
necessary in future to extend and clarify these findings.  
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The development of VSCC after VIN treatment is relatively high compared to 
progression after treatment of CIN. 30  This may be due to widespread field 
change over the perineal area; in the group that underwent HPV testing nine of 
the 14 cases that progressed had severe dysplasia at another perineal/genital 
site. In addition, technically it is more challenging to treat vulvar disease 
compared to cervical disease.  Unfortunately, unlike cervical disease, there is 
no equitable screening and recall system for VIN. Our study indicates that 
development of such a system would be advantageous because of the 
significant length of time taken for progression from VIN to VSCC and the 
opportunity for an intervention to prevent VSCC. Cellular biomarkers which 
have been interrogated in the vulvar context have included chemokine receptor 
proteins 31, p16 and p53 10 and ROCK1 protein.32  Charting the loss or gain of 
viral biomarkers 33 may shed significant light on the unusual aetiology of VIN 
and progression to VSCC. 
 
With respect to HPV status, HPV infection was identified in 87% of VIN cases 
with HPV type 16 and/or 18 present in 78% of these.  Comparatively, HPV was 
detected in 52% of VSCC cases with HPV 16 identified in 48% of cases. VSCC 
surrounded by VIN was much more likely to be HR-HPV positive and may 
represent widespread perineal/genital HPV infection and field change caused 
by the virus. There is a paucity of contemporary data in the UK on type-specific 
prevalence of HPV in vulval disease. The limitation of this and other studies is 
that vulvar disease is relatively rare. Consequently, these data are important to 
help inform the potential impact of the prophylactic HPV vaccines on vulval 
disease, particularly as vaccine uptake rates in the UK have been consistently 
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high (>90%) since introduction in 2008.34 HPV status was significantly 
associated with age in our study.  Our data indicates that the prophylactic HPV 
vaccine will prevent about half the cases of VSCC under the age of 69 years. It 
should be noted that a number of cases of VIN were associated with HPV 33, 
which would be prevented by immunisation with bivalent vaccine through cross-
protection but would not be prevented by the quadrivalent vaccine currently 
used as part of the national programme.35 
 
One key finding of this study was that women who had HPV-positive VSCC had 
a significantly improved prognosis compared to those who had HPV negative 
tumours, and that this observation was maintained after adjustment for age at 
diagnosis and tumour stage. This observation reconciles with the recent study 
of Hay et al (2016) who assessed the impact of HPV status (through HPV 
specific PCR and p16 staining) and p53 mutation status in series of 92 VSCC 
diagnosed between 1998-2007.10 Notably HPV positive (and p16 positive) 
patients were less likely to have recurrence and there were no VSCC related 
deaths whereas p53-mutatant positive patients had a greater probability of 
recurrence and were significantly more likely to die from VSCC. While we did 
not measure p53 status in the present study ± the observation that HPV status 
confers a favourable outcome is consistent.    It is now well established that 
HPV positive OPSCC is associated with improved clinical outcomes and 
annotation of OPSCC for HPV status to provide clinicians with insight into a 
SDWLHQWV¶SURJQRVLVLVEHFRPLQJPRUHZLGHVSUHDG. 7 Furthermore, although the 
relative proportions are small ± cervical cancers where no HR-HPV is detected 
have been shown to have a worse outcome. 8  The drivers as to why HPV 
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associated neoplasms are associated with improved outcomes compared to 
their HPV negative counterparts are not fully established and are complicated 
by influential confounders, particularly smoking which is often challenging to 
document accurately.  However the higher levels of host-mutation associated 
with non HR-HPV cancers may explain the differential outcome at least in part.   
 
To conclude, the management of VIN remains a challenge. While HPV 
immunisation will significantly impact on this disease, the benefits realisation 
will take time and will not protect against all cases ± including HPV-negative 
cases of VSCC, which appear to have a worse prognosis. HPV testing should 
be considered routine for VSCC management, to guide prognosis and to drive 
development of novel approaches in treatment. While much has been invested 
in the development of biomarkers for the improved management of pre-invasive 
cervical disease there is a comparative lack of studies in the VIN context ± more 
are needed to inform and support the improved management of this complex, 
disease which appears to be increasing in incidence.  
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A. Overall survival according to high-risk 
HPV status 
B. Overall survival according to age at 
diagnosis  
 
  
C. Overall survival according to tumour 
FIGO stage  
D. Overall survival according to the 
presence of tumour-associated VIN 
(none vs. present) 
  
E. Overall survival according to smoking 
status 
F. Overall survival according to p16 
status 
  
Figure 1. Kaplan-Meier estimates for Overall survival among women with VSCC. 
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A. Progression-free survival according to 
high-risk HPV status 
B. Progression-free survival according to 
age at diagnosis  
 
  
C. Progression-free survival according to 
tumour FIGO stage  
D. Progression-free survival according to 
the presence of tumour-associated VIN 
(none vs. present) 
  
E. Progression-free survival according to 
smoking status 
F. Progression-free survival according to 
p16 status 
  
Figure 2. Kaplan-Meier estimates for progression-free survival among women with 
VSCC. 
 
